Actuate Therapeutics (ACTU) Stock Price, News & Analysis

Company Overview

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors. By inhibiting CDK9, atuveciclib is designed to disrupt transcription-dependent survival pathways in malignant cells. In addition to its CDK9 program, Actuate is advancing preclinical research on a tumor-homing peptide–drug conjugate that aims to selectively deliver cytotoxic payloads to integrin-expressing tumor cells, thereby enhancing therapeutic index and minimizing off-target effects.

Since its founding in 2018, Actuate has built its research and development operations in the San Francisco Bay Area, leveraging collaborations with leading academic institutions and contract research organizations. The company’s clinical trials are currently conducted at premier oncology centers across the United States, with plans to expand its geographic footprint into Europe and Asia as its pipeline advances through development milestones.

Actuate’s leadership team comprises industry veterans with extensive experience in oncology research, translational science and biopharmaceutical commercialization. By combining deep scientific expertise with a streamlined development strategy, the company aims to rapidly advance its targeted therapies toward clinical proof of concept and ultimately to regulatory approval.

Key Stats

• Today's Range: $1.92 to $2.05
• 50-Day Range: $1.82 to $3.34
• 52-Week Range: $1.58 to $9.22
• Volume: 60,626 shs
• Average Volume: 159,400 shs
• Market Capitalization: $46.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.50
• Consensus Rating: Hold

Actuate Therapeutics Stock Analysis - MarketRank™

Actuate Therapeutics scored higher than 34% of companies evaluated by MarketBeat, and ranked 679th out of 849 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Actuate Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Actuate Therapeutics has a consensus price target of $17.50, representing about 797.4% upside from its current price of $1.95.

Amount of Analyst Coverage

Actuate Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Actuate Therapeutics are expected to grow in the coming year, from ($0.86) to ($0.78) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Actuate Therapeutics is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Actuate Therapeutics is -2.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Actuate Therapeutics has a P/B Ratio of 5.74. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.16% of the float of Actuate Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Actuate Therapeutics has a short interest ratio ("days to cover") of 8.96.

Change versus previous month

Short interest in Actuate Therapeutics has recently increased by 4.24%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Actuate Therapeutics does not currently pay a dividend.

Dividend Growth

Actuate Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for ACTU on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

MarketBeat Follows

4 people have added Actuate Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Actuate Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

57.98% of the stock of Actuate Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Actuate Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 6/24/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ACTU
• Previous Symbol: NASDAQ:ACTU
• CIK: 1652935
• Web: N/A
• Phone: (847) 986-4190
• Fax: N/A
• Employees: 10
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Actuate Therapeutics: $17.50
• High Price Target: $20.00
• Low Price Target: $15.00
• Potential Upside/Downside: +797.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.97)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$22.23 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -430.93%
• Return on Assets: -180.86%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.80
• Quick Ratio: 1.80

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.34 per share
• Price / Book: 5.74

Miscellaneous

• Outstanding Shares: 23,930,000
• Free Float: 10,054,000
• Market Cap: $46.66 million
• Optionable: N/A
• Beta: 0.52